DOP2018000122A - Aglutinantes de tnf mejorados - Google Patents
Aglutinantes de tnf mejoradosInfo
- Publication number
- DOP2018000122A DOP2018000122A DO2018000122A DO2018000122A DOP2018000122A DO P2018000122 A DOP2018000122 A DO P2018000122A DO 2018000122 A DO2018000122 A DO 2018000122A DO 2018000122 A DO2018000122 A DO 2018000122A DO P2018000122 A DOP2018000122 A DO P2018000122A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- tnf
- isvd
- polypeptides
- bind
- compounds
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 3
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Organic Insulating Materials (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562254375P | 2015-11-12 | 2015-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2018000122A true DOP2018000122A (es) | 2018-09-30 |
Family
ID=57348648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2018000122A DOP2018000122A (es) | 2015-11-12 | 2018-05-11 | Aglutinantes de tnf mejorados |
Country Status (37)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| PH12013502669B1 (en) | 2011-06-23 | 2018-08-10 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| RU2746738C2 (ru) | 2014-05-16 | 2021-04-20 | Аблинкс Нв | Улучшенные вариабельные домены иммуноглобулина |
| KR20250099289A (ko) | 2014-05-16 | 2025-07-01 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
| NO2768984T3 (index.php) * | 2015-11-12 | 2018-06-09 | ||
| GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| JP7719775B2 (ja) | 2019-12-06 | 2025-08-06 | アブリンクス エン．ヴェー． | ＴＮＦαおよびＯＸ４０Ｌを標的とする免疫グロブリン単一可変ドメインを含むポリペプチド |
| IL293561A (en) | 2019-12-06 | 2022-08-01 | Ablynx Nv | Polypeptides comprising immunoglobulin with one variable domain targeting TNFa and IL-23 |
| CN112300289B (zh) * | 2019-12-30 | 2022-06-10 | 中国药科大学 | RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用 |
| US11897951B2 (en) * | 2020-12-18 | 2024-02-13 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α |
| US20250026842A1 (en) * | 2021-11-29 | 2025-01-23 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Modified protein or polypeptide |
| AU2023373192A1 (en) * | 2022-11-04 | 2025-04-17 | St. Jude Children's Research Hospital, Inc. | Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases |
| US20240415974A1 (en) | 2022-12-23 | 2024-12-19 | Ablynx N.V. | Protein-based conjugation carriers |
| AU2024221136A1 (en) | 2023-02-17 | 2025-10-02 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| AU2152299A (en) | 1997-10-27 | 1999-05-24 | Unilever Plc | Multivalent antigen-binding proteins |
| US20020155604A1 (en) | 1998-02-19 | 2002-10-24 | Jeffrey A. Ledbetter | Compositions and methods for regulating lymphocyte activation |
| WO2004081026A2 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Polypeptides |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| EP2284192A3 (en) * | 2002-11-08 | 2011-07-20 | Ablynx N.V. | Camelidae antibodies for sublingual administration |
| MXPA05006043A (es) | 2003-01-10 | 2006-01-30 | Ablynx Nv | Polipeptidos terapeuticos, homologos de los mismos, fragmentos de los mismos y para uso al modular la agregacion mediada de plaquetas. |
| AU2003283136A1 (en) | 2003-11-07 | 2005-05-26 | Ablynx N.V. | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
| KR20070084170A (ko) | 2004-10-13 | 2007-08-24 | 아블린쓰 엔.브이. | 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드 |
| EP1863847A2 (en) | 2004-12-02 | 2007-12-12 | Domantis Limited | Anti-il-1r1 single domain antibodies and therapeutic uses |
| LT2949668T (lt) * | 2005-05-18 | 2019-11-11 | Ablynx Nv | Pagerinti nanokūnai tm prieš navikų nekrozės faktorių alfa |
| TR201815552T4 (tr) | 2005-05-20 | 2018-11-21 | Ablynx Nv | Agregasyon ile ilgili hastalıkların tedavisine yönelik iyileştirilmiş nanoantikorlar (TM). |
| DE102005023617A1 (de) * | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
| WO2007025977A2 (en) | 2005-08-30 | 2007-03-08 | Actogenix Nv | Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis |
| CA2629850A1 (en) | 2005-12-01 | 2007-06-07 | Domantis Limited | Competitive domain antibody formats that bind interleukin 1 receptor type 1 |
| EP1957536A2 (en) | 2005-12-01 | 2008-08-20 | Domantis Limited | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 |
| FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
| EP2441838A3 (en) | 2006-01-24 | 2013-07-10 | Domantis Limited | Fusion proteins that contain natural junctions |
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| AU2007328900A1 (en) | 2006-12-05 | 2008-06-12 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| WO2008142164A2 (en) | 2007-05-24 | 2008-11-27 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| JP2011504740A (ja) | 2007-11-27 | 2011-02-17 | アブリンクス エン．ヴェー． | ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド |
| DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
| AU2009248049B2 (en) | 2008-05-16 | 2015-07-23 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
| WO2010094720A2 (en) * | 2009-02-19 | 2010-08-26 | Glaxo Group Limited | Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists |
| JP5647222B2 (ja) | 2009-04-10 | 2014-12-24 | アブリンクス エン．ヴェー． | Ｉｌ−６ｒ関連疾患及び障害の治療のためのｉｌ−６ｒに指向性を有する改善されたアミノ酸配列及びこれを含むポリペプチド |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| EA201270174A1 (ru) | 2009-07-16 | 2012-07-30 | Глэксо Груп Лимитед | Отдельные связывающиеся вариабельные домены с улучшенными свойствами, направленные против сывороточного альбумина |
| US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| AU2012234284B2 (en) | 2011-03-28 | 2015-10-08 | Ablynx Nv | Bispecific anti-CXCR7 immunoglobulin single variable domains |
| AU2012271974B2 (en) | 2011-06-23 | 2017-01-12 | Ablynx Nv | Serum albumin binding proteins |
| PH12013502669B1 (en) * | 2011-06-23 | 2018-08-10 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| MX2014001883A (es) * | 2011-08-17 | 2014-05-27 | Glaxo Group Ltd | Proteinas y peptidos modificados. |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| RU2746738C2 (ru) * | 2014-05-16 | 2021-04-20 | Аблинкс Нв | Улучшенные вариабельные домены иммуноглобулина |
| NO2768984T3 (index.php) * | 2015-11-12 | 2018-06-09 | ||
| JP7540877B2 (ja) * | 2016-02-12 | 2024-08-27 | アブリンクス エン．ヴェー． | 免疫グロブリン単一可変ドメインの生成方法 |
-
2012
- 2012-10-19 NO NO12841612A patent/NO2768984T3/no unknown
-
2016
- 2016-11-13 MA MA041653A patent/MA41653A/fr unknown
- 2016-11-14 TN TNP/2018/000159A patent/TN2018000159A1/en unknown
- 2016-11-14 SG SG11201803975SA patent/SG11201803975SA/en unknown
- 2016-11-14 JP JP2018524836A patent/JP6962915B2/ja active Active
- 2016-11-14 ME MEP-2017-291A patent/ME02954B/me unknown
- 2016-11-14 CN CN201680076588.6A patent/CN108473563B/zh active Active
- 2016-11-14 SM SM20170590T patent/SMT201700590T1/it unknown
- 2016-11-14 CA CA3005085A patent/CA3005085C/en active Active
- 2016-11-14 MX MX2018005992A patent/MX385207B/es unknown
- 2016-11-14 IL IL259269A patent/IL259269B2/en unknown
- 2016-11-14 CR CR20180311A patent/CR20180311A/es unknown
- 2016-11-14 EP EP16798122.4A patent/EP3191511B1/en active Active
- 2016-11-14 WO PCT/EP2016/077595 patent/WO2017081320A1/en not_active Ceased
- 2016-11-14 PL PL16798122T patent/PL3191511T3/pl unknown
- 2016-11-14 MD MDE20170066T patent/MD3191511T2/ro unknown
- 2016-11-14 SI SI201630013T patent/SI3191511T1/en unknown
- 2016-11-14 KR KR1020247005963A patent/KR20240029115A/ko active Pending
- 2016-11-14 RS RS20171299A patent/RS56676B1/sr unknown
- 2016-11-14 PE PE2018000766A patent/PE20181317A1/es unknown
- 2016-11-14 AU AU2016352943A patent/AU2016352943B2/en active Active
- 2016-11-14 IL IL310373A patent/IL310373A/en unknown
- 2016-11-14 US US15/501,011 patent/US10544211B2/en active Active
- 2016-11-14 EP EP17184686.8A patent/EP3266798A3/en not_active Withdrawn
- 2016-11-14 DK DK16798122.4T patent/DK3191511T3/en active
- 2016-11-14 HR HRP20171949TT patent/HRP20171949T1/hr unknown
- 2016-11-14 CA CA3234178A patent/CA3234178A1/en active Pending
- 2016-11-14 LT LTEP16798122.4T patent/LT3191511T/lt unknown
- 2016-11-14 HU HUE16798122A patent/HUE035805T2/en unknown
- 2016-11-14 ES ES16798122.4T patent/ES2662418T3/es active Active
- 2016-11-14 BR BR112018009714A patent/BR112018009714A8/pt active Search and Examination
- 2016-11-14 KR KR1020187016731A patent/KR102641194B1/ko active Active
- 2016-11-14 PT PT167981224T patent/PT3191511T/pt unknown
-
2017
- 2017-03-13 US US15/456,824 patent/US9745372B2/en active Active
- 2017-12-01 HK HK18108106.4A patent/HK1248716A1/en unknown
- 2017-12-19 CY CY20171101330T patent/CY1120303T1/el unknown
-
2018
- 2018-05-11 GT GT201800095A patent/GT201800095A/es unknown
- 2018-05-11 CL CL2018001291A patent/CL2018001291A1/es unknown
- 2018-05-11 DO DO2018000122A patent/DOP2018000122A/es unknown
- 2018-05-15 PH PH12018501025A patent/PH12018501025A1/en unknown
- 2018-06-05 EC ECIEPI201842569A patent/ECSP18042569A/es unknown
- 2018-06-08 CO CONC2018/0005915A patent/CO2018005915A2/es unknown
-
2021
- 2021-10-14 JP JP2021168871A patent/JP7357038B2/ja active Active
-
2023
- 2023-01-10 AU AU2023200113A patent/AU2023200113A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2018000122A (es) | Aglutinantes de tnf mejorados | |
| EA201792572A1 (ru) | Антитела к ox40 и их применение | |
| ECSP19011185A (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123 | |
| MX2023003630A (es) | Aglutinantes de albumina de suero mejorados. | |
| PH12016502267A1 (en) | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof | |
| EA201891121A1 (ru) | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения | |
| EA201891366A1 (ru) | Гуманизированные антитела против cd73 | |
| EA201892616A1 (ru) | Антитела к pd1 и lag3 для лечения злокачественного новообразования | |
| MX388739B (es) | Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso. | |
| AR091069A1 (es) | Proteinas de union a antigeno dirigidas contra el receptor st2 | |
| UY36561A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
| MX380414B (es) | Polipeptidos biparatopicos que antagonizan la señalizacion wnt en celulas tumorales. | |
| MX373485B (es) | Miembros de unión al factor de necrosis tumoral (tnf) alfa. | |
| MX2021000155A (es) | Moleculas de proteina multifuncionales que comprenden decorina y su uso. | |
| MX2024005945A (es) | Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos. | |
| EA201400924A1 (ru) | Сконструированные пестицидные белки | |
| EA201691589A1 (ru) | Стабилизированные основанные на фибронектине каркасные молекулы | |
| SA518400027B1 (ar) | TNF- a أجسام مضادة لـ وشظايا وظيفية منها | |
| EA201991088A1 (ru) | Связывающие пептиды | |
| EA202090533A2 (ru) | Антитела к ox40 и их применение | |
| AR100744A1 (es) | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos |